{"entity":{"id":"nct06903377","kind":"trial","name":"Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of Gecacitinib in non-small-cell lung cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","summary":"Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06903377 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 50 participants planned, started 2025-05-23 and due to reach its primary completion in 2027-04. Interventions recorded: ZG005 for Injection and Gecacitinib Hydrochloride Tablets.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06903377","url":"https://clinicaltrials.gov/study/NCT06903377"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["gecacitinib"],"companies":["zelgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06903377","phase":"1/2","setting":"A Multicenter, Open-label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","enrolled":50,"outcomes":[]},"route":"/trials/nct06903377/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"gecacitinib","kind":"drug","name":"Gecacitinib","route":"/drugs/gecacitinib/"}],"company":[{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/"}]}}